<DOC>
	<DOC>NCT00791700</DOC>
	<brief_summary>The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents. This study will also determine whether maraviroc is safe to use in children and adolescents.</brief_summary>
	<brief_title>An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects who are 218 years of age, treatment experienced for 6 months or longer with at least 2 ARV drug classes, with HIV1 RNA ≥1,000 copies/mL X4 or dual/mixedtropic virus detected by the Trofile™ viral tropism assay Concomitant therapy with other investigational agents (other than experimental ARV agents available through preapproval access programs) Known ≥Grade 3 of any of the following laboratory tests at Screening or within 30 days prior to Baseline Visit: Neutrophil count, hemoglobin, platelets, AST, ALT, and creatinine, lipase; Total bilirubin ≥Grade 3, unless ALL of the following are true: Current regimen includes atazanavir; ALT/AST &lt; 2.5 X ULN; No symptoms other than jaundice or icterus. Other laboratory values ≥Grade 3, must be reviewed by Pfizer.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Open label pharmacokinetic safety and efficacy in HIV-1 infected pediatrics</keyword>
</DOC>